We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against other most expensive stocks insiders are dumping in March.

After being in the green for a few trading sessions, the broader market index slid 0.8% on Wednesday, and blue-chip companies declined 0.1%. The NASDAQ Composite was down 1.6% in the early afternoon. On Tuesday, Trump provided an update on tariffs, saying they will likely be more “lenient than reciprocal,” suggesting a more relaxed approach, reports CNBC.

As investors process daily market developments, uncertainty continues to impact the market. In these periods, insider trading often attracts attention, as purchases of company stock by executives may suggest confidence in the company’s future. However, insider selling doesn’t necessarily imply a lack of faith—it may be driven by personal financial needs or a desire for diversification. Executives frequently rely on pre-established plans, such as 10b5-1, to maintain transparency. While insider trading can provide useful insights, it should be evaluated in the context of a company’s financial health, market trends, and industry changes.

What are some of the most expensive stocks insiders have been selling this month so far? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least three insiders had sold shares in March. From there, we ranked the 20 stocks with the highest average price per share in times of sales.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

With each stock, we note the average price per share of these sales and the stock’s market capitalization.

A scientist examining the results of a Phase III clinical trial for non-alcoholic steatohepatitis.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Market Capitalization: $7.47 billion

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company based in West Conshohocken, Pennsylvania, focused on developing novel treatments for metabolic dysfunction-associated steatohepatitis (MASH). The company’s Rezdiffra (resmetirom) is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to treat MASH with moderate to advanced fibrosis. An ongoing Phase 3 trial is evaluating Rezdiffra for treating compensated MASH cirrhosis.

For the full year 2024, Madrigal Pharmaceuticals (NASDAQ:MDGL) reported net revenues of $180.1 million. No product sales were recognized during the comparable prior year period. As of Dec. 31, 2024, Madrigal had cash, cash equivalents, restricted cash and marketable securities of $931.3 million, compared to $634.1 million at Dec. 31, 2023.

In recent developments, Madrigal Pharmaceuticals (NASDAQ:MDGL) announced FDA approval of Rezdiffra for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

This month, five insiders, including the CFO, sold approximately $11.36 million worth of Madrigal shares at an average price of $330.33 per share. Currently, the stock trades at $338.49 per share, having gained 9.69% year-to-date and 36.70% over the past 12 months.

Ten analysts have given an average “Moderate Buy” rating on Madrigal stock with a price target of $378.44. The average price target suggests a potential upside of 11.79% from the latest price.

Overall, MDGL ranks 16th on our list of most expensive stocks insiders are dumping in March. While we acknowledge the potential of MDGL our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDGL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.